NCT07441291 2026-02-27
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital
Phase 3 Recruiting
Clinical Trials
25 trialsNCT01499394 2026-01-21
Caris Biorepository Research Protocol
Caris Science, Inc.
Recruiting
NCT07356882 2026-01-21
EURHOLY
Assistance Publique - Hôpitaux de Paris
Recruiting
NCT05595408 2025-12-09
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
RenJi Hospital
Recruiting
NCT07257380 2025-12-02
MRD-ATLAS
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07178847 2025-12-01
NeckTAR-IN
Centre Jean Perrin
Phase NA Recruiting
NCT06287749 2025-07-10
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
University Hospital, Montpellier
Recruiting
NCT05479708 2025-04-24
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Ruijin Hospital
Enrolling by invitation
NCT06941987 2025-04-24
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Shanghai Zhongshan Hospital
Not yet recruiting
NCT05198154 2025-04-23
CR1STAL
Second Xiangya Hospital of Central South University
Recruiting
NCT06763302 2025-01-08
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The Children's Hospital of Zhejiang University School of Medicine
Phase NA Not yet recruiting
NCT05601830 2024-11-06
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
NCT05117879 2024-10-17
R0 Resection Rate Between CSP, cEMR and hEMR for 1-2 cm Colorectal SSLs
National Taiwan University Hospital
Phase NA Completed
NCT05623267 2023-08-07
SURPASS
Sun Yat-sen University
Phase 2/3 Recruiting
NCT05956977 2023-07-24
Neuro3DUS
University of Ulm
Phase NA Unknown
NCT04853420 2023-05-10
MARTINI
University of Leicester
Active not recruiting
NCT05603156 2022-11-02
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT04321577 2021-09-02
Validation of a Score That Predicts Residual Disease in Incidental Gallbladder Cancer
Hospital Universitari de Bellvitge
Withdrawn
NCT02900625 2021-01-27
VMRDO
Centre Hospitalier Universitaire de Besancon
Completed
NCT03662087 2018-09-07
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03624530 2018-08-10
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03491033 2018-04-10
Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy
Yonsei University
Completed
NCT02400827 2015-03-27
OVAMAR
University Hospital, Clermont-Ferrand
Unknown
NCT02400970 2015-03-27
TESTIMAR
University Hospital, Clermont-Ferrand
Unknown
NCT00172068 2009-12-23
MRD-1
Novartis
Phase 2 Terminated